Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction

Leukemia 2026

View at publisher
Authors: Marianne Ayoub, Casilda Hitier, Léa Dehgane, Eliane Mallet, Mariana Tannoury, Ivan Nemazanyy, Damien Roos‐Weil, Karim Maloum, Ingo Ringshausen, Élise Chapiro, F. Florence Nguyen‐Khac, Delphine Garnier
+3 more Marie Lagouge, Letícia Koch Lerner, Santos A. Susín
DOI: 10.1038/s41375-025-02846-6
Cited by: 0
References: 15

Fields of Study & Subjects

PARP inhibition in cancer therapy Chronic Lymphocytic Leukemia Research Cell death mechanisms and regulation

Publication details

Journal / source
Leukemia
Volume
40
Issue
2
Pages
449–453
Publication date
7 January 2026
Language
EN